chr16-56887967-G-A

Variant summary

Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PM1PP2PP5_Very_Strong

The NM_001126108.2(SLC12A3):​c.2221G>A​(p.Gly741Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000764 in 1,612,942 control chromosomes in the GnomAD database, with no homozygous occurrence. 13/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).

Frequency

Genomes: 𝑓 0.00041 ( 0 hom., cov: 30)
Exomes 𝑓: 0.00080 ( 0 hom. )

Consequence

SLC12A3
NM_001126108.2 missense

Scores

15
3
1

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:26

Conservation

PhyloP100: 9.83

Publications

30 publications found
Variant links:
Genes affected
SLC12A3 (HGNC:10912): (solute carrier family 12 member 3) This gene encodes a renal thiazide-sensitive sodium-chloride cotransporter that is important for electrolyte homeostasis. This cotransporter mediates sodium and chloride reabsorption in the distal convoluted tubule. Mutations in this gene cause Gitelman syndrome, a disease similar to Bartter's syndrome, that is characterized by hypokalemic alkalosis combined with hypomagnesemia, low urinary calcium, and increased renin activity associated with normal blood pressure. This cotransporter is the target for thiazide diuretics that are used for treating high blood pressure. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
SLC12A3 Gene-Disease associations (from GenCC):
  • Gitelman syndrome
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 11 ACMG points.

PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 8 uncertain in NM_001126108.2
PP2
Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 138 curated pathogenic missense variants (we use a threshold of 10). The gene has 18 curated benign missense variants. Gene score misZ: -0.93606 (below the threshold of 3.09). Trascript score misZ: 0.71313 (below the threshold of 3.09). GenCC associations: The gene is linked to Gitelman syndrome.
PP5
Variant 16-56887967-G-A is Pathogenic according to our data. Variant chr16-56887967-G-A is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 208612.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SLC12A3NM_001126108.2 linkc.2221G>A p.Gly741Arg missense_variant Exon 18 of 26 ENST00000563236.6 NP_001119580.2 P55017-1
SLC12A3NM_000339.3 linkc.2221G>A p.Gly741Arg missense_variant Exon 18 of 26 NP_000330.3 P55017-2
SLC12A3NM_001126107.2 linkc.2218G>A p.Gly740Arg missense_variant Exon 18 of 26 NP_001119579.2 P55017-3
SLC12A3NM_001410896.1 linkc.2218G>A p.Gly740Arg missense_variant Exon 18 of 26 NP_001397825.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SLC12A3ENST00000563236.6 linkc.2221G>A p.Gly741Arg missense_variant Exon 18 of 26 1 NM_001126108.2 ENSP00000456149.2 P55017-1
SLC12A3ENST00000438926.6 linkc.2221G>A p.Gly741Arg missense_variant Exon 18 of 26 1 ENSP00000402152.2 P55017-2
SLC12A3ENST00000566786.5 linkc.2218G>A p.Gly740Arg missense_variant Exon 18 of 26 1 ENSP00000457552.1 P55017-3
SLC12A3ENST00000262502.5 linkc.2218G>A p.Gly740Arg missense_variant Exon 18 of 26 5 ENSP00000262502.5 J3QSS1

Frequencies

GnomAD3 genomes
AF:
0.000408
AC:
62
AN:
151816
Hom.:
0
Cov.:
30
show subpopulations
Gnomad AFR
AF:
0.000121
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000131
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000794
Gnomad OTH
AF:
0.000479
GnomAD2 exomes
AF:
0.000370
AC:
93
AN:
251298
AF XY:
0.000346
show subpopulations
Gnomad AFR exome
AF:
0.000123
Gnomad AMR exome
AF:
0.000202
Gnomad ASJ exome
AF:
0.000199
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000695
Gnomad OTH exome
AF:
0.000326
GnomAD4 exome
AF:
0.000802
AC:
1171
AN:
1461010
Hom.:
0
Cov.:
31
AF XY:
0.000788
AC XY:
573
AN XY:
726842
show subpopulations
African (AFR)
AF:
0.000120
AC:
4
AN:
33458
American (AMR)
AF:
0.000313
AC:
14
AN:
44704
Ashkenazi Jewish (ASJ)
AF:
0.000383
AC:
10
AN:
26112
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39668
South Asian (SAS)
AF:
0.0000232
AC:
2
AN:
86252
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53222
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5766
European-Non Finnish (NFE)
AF:
0.00101
AC:
1120
AN:
1111488
Other (OTH)
AF:
0.000348
AC:
21
AN:
60340
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.467
Heterozygous variant carriers
0
54
108
161
215
269
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
46
92
138
184
230
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000408
AC:
62
AN:
151932
Hom.:
0
Cov.:
30
AF XY:
0.000390
AC XY:
29
AN XY:
74276
show subpopulations
African (AFR)
AF:
0.000121
AC:
5
AN:
41418
American (AMR)
AF:
0.000131
AC:
2
AN:
15268
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5156
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4814
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10528
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000795
AC:
54
AN:
67966
Other (OTH)
AF:
0.000474
AC:
1
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.523
Heterozygous variant carriers
0
3
7
10
14
17
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000549
Hom.:
0
Bravo
AF:
0.000389
TwinsUK
AF:
0.000539
AC:
2
ALSPAC
AF:
0.000519
AC:
2
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000581
AC:
5
ExAC
AF:
0.000404
AC:
49
EpiCase
AF:
0.000382
EpiControl
AF:
0.000889

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:26
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Familial hypokalemia-hypomagnesemia Pathogenic:13
Feb 10, 2025
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: SLC12A3 c.2221G>A (p.Gly741Arg) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00037 in 251298 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in SLC12A3 causing Familial Hypokalemia-Hypomagnesemia, allowing no conclusion about variant significance. c.2221G>A has been reported in the literature in multiple individuals affected with Familial Hypokalemia-Hypomagnesemia (example: Ashton_2018). These data indicate that the variant is very likely to be associated with disease. The following publication has been ascertained in the context of this evaluation (PMID: 29398133). ClinVar contains an entry for this variant (Variation ID: 208612). Based on the evidence outlined above, the variant was classified as pathogenic. -

Dec 06, 2018
CENTOGENE GmbH and LLC - Guiding Precision Medicine
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Oct 26, 2021
MGZ Medical Genetics Center
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 17, 2023
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Gitelman syndrome (MIM#263800). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from glycine to arginine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (104 heterozygotes, 0 homozygotes). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools and highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated SLC12 family domain (DECIPHER). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been classified as pathogenic by at least fifteen clinical diagnostic laboratories and has been reported as one of the five most frequent pathogenic missense variants associated with Gitelman syndrome in Caucasians (ClinVar; PMID: 35591852). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -

Apr 27, 2022
European Hospital Georges Pompidou Genetics Department, Assistance Publique - Hôpitaux de Paris AP-HP
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

ACMG criteria used:PS3 PS4 PM1 PM2 PM3 PP3 PP5 -

-
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant has been previously reported as a compound heterozygous change in patients with Gitelman syndrome (PMID: 8528245, 17329572, 21415153, 22009145, 23328711, 32939031). Functional studies have shown that this change results in reduced sodium uptake (PMID: 12039972). The c.2221G>A (p.Gly741Arg) variant is present in the heterozygous state in the gnomAD population database at a frequency of 0.03685% (104/282254) and is absent in the homozygous state, thus it is presumed to be rare. The c.2221G>A (p.Gly741Arg) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.2221G>A (p.Gly741Arg) variant is classified as Pathogenic. -

Jun 30, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Dec 20, 2022
Genetics and Molecular Pathology, SA Pathology
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The SLC12A3 c.2221G>A variant is classified as Pathogenic (PS3, PM3_strong2, PP3) The SLC12A3 c.2221G>A variant is a single nucleotide change in exon 18/26 of the SLC12A3 gene, which is predicted to change the amino acid glycine at position 741 in the protein to arginine. Functional studies show that the variant results in a non-functional protein (PMID:12039972)(PS3). This variant has been detected in trans with pathogenic variants for this recessive condition (PMID:17329572) (PM3_strong). Computational predictions support a deleterious effect on the gene or gene product (PP3). The variant has been reported in dbSNP (rs138977195), in population databases (gnomAD 62/151816, 0 homs, highest freq 0.079% non-Finnish European) and as disease causing in the HGMD database (CM961300). It has been reported as Conflicting interpretations of pathogenicity by other diagnostic laboratories (ClinVar Variation ID: 208612). The variant has been widely reported in the literature in patients with Gitelman syndrome and has been described as a hotspot mutation (PMID:8528245, 12039972, 17329572, 21415153, 22009145). -

Mar 24, 2022
Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PS3, PM2, PM3_Strong, PP3 -

Jul 15, 2021
Genome-Nilou Lab
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 12, 2021
Revvity Omics, Revvity
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 28, 2017
Illumina Laboratory Services, Illumina
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Across a selection of the available literature, the SLC12A3 c.2221G>A (p.Gly741Arg) missense variant has been reported in four patients with Gitelman syndrome in a homozygous state and in 79 patients in a compound heterozygous state (Simon et al. 1996; Vargas-Poussou et al. 2011; Glaudemans et al. 2012; Berry et al. 2013; Dongilli et al. 2016). Control data are not available for this variant which is reported at a frequency of 0.00063 in the European (non-Finnish) population of the Exome Aggregation Consortium. Functional studies in Xenopus oocytes demonstrated that the p.Gly741Arg variant resulted in no sodium ion uptake activity, showed intracellular localization rather than plasma membrane localization compared to wild type, and was not glycosylated (De Jong et al. 2002). Based on the collective evidence, the p.Gly741Arg variant is classified as pathogenic for Gitelman syndrome. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -

Feb 05, 2022
DASA
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.2221G>A;p.(Gly741Arg) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 208612; PMID: 18391953; 17329572; 21415153; 22009145; 23328711; 8528245) - PS4. The variant is present at low allele frequencies population databases (rs138977195 – gnomAD 0.0004084%; ABraOM no frequency - http://abraom.ib.usp.br/) - PM2_supporting. The variant co-segregated with disease in multiple affected family members (PMID: 8528245) - PP1. In summary, the currently available evidence indicates that the variant is likely pathogenic. -

not provided Pathogenic:9
Jun 01, 2019
CeGaT Center for Human Genetics Tuebingen
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Oct 11, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 741 of the SLC12A3 protein (p.Gly741Arg). This variant is present in population databases (rs138977195, gnomAD 0.07%). This missense change has been observed in individual(s) with Gitelman syndrome (PMID: 8528245, 17329572, 18391953, 21415153, 22009145, 23328711). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 208612). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt SLC12A3 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects SLC12A3 function (PMID: 12039972). For these reasons, this variant has been classified as Pathogenic. -

Jan 06, 2022
GeneDx
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

In vitro functional analysis demonstrated significantly diminished metolazone-sensitive sodium uptake levels in cells harboring this variant; immunocytochemical analysis revealed that the altered protein was predominantly localized to the cytoplasm rather than the plasma membrane as observed with the wild-type protein (De Jong et al., 2002); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 8528245, 18391953, 10988270, 9734597, 30201548, 23328711, 17329572, 21415153, 22009145, 26921350, 30596175, 31916727, 31980526, 30136149, 32939031, 31672324, 12039972, 27535533) -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

May 15, 2023
Clinical Genetics Laboratory, Skane University Hospital Lund
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Sep 28, 2023
Mayo Clinic Laboratories, Mayo Clinic
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PP3, PM3_very_strong, PS3_supporting, PS4 -

Sep 16, 2018
Gharavi Laboratory, Columbia University
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:research

- -

Jan 11, 2024
Athena Diagnostics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The frequency of this variant in the general population is consistent with pathogenicity. (http://gnomad.broadinstitute.org) Assessment of experimental evidence suggests this variant results in abnormal protein function. (PMID: 12039972) In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Bartter syndrome;C0268450:Familial hypokalemia-hypomagnesemia Pathogenic:1
Apr 05, 2018
Sydney Genome Diagnostics, Children's Hospital Westmead
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

This individual is heterozygous for the c.2221G>A variant in the SLC12A3 gene. This variant has been widely reported in numerous patients with Gitelman syndrome in the literature (Vargas-Poussou et al 2011 J Am Soc Nephrol 22:693-703. This variant is considered to be pathogenic according to the ACMG guidelines. -

Inherited renal tubular disease Pathogenic:1
Sep 07, 2017
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

proposed classification - variant undergoing re-assessment, contact laboratory -

SLC12A3-related disorder Pathogenic:1
Feb 22, 2024
PreventionGenetics, part of Exact Sciences
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

The SLC12A3 c.2221G>A variant is predicted to result in the amino acid substitution p.Gly741Arg. This variant has been reported in many unrelated individuals to be pathogenic for Gitelman syndrome (Simon et al. 1996. PubMed ID: 8528245; De Jong et al. 2002. PubMed ID: 12039972; Supp. Table 1 in Fujimura et al. 2018. PubMed ID: 30596175; Supp. Table S1 in Hureaux et al. 2019. PubMed ID: 31672324; Zacchia et al. 2021. PubMed ID: 33964006). Functional studies indicate that the p.Gly741Arg change impacts protein function (De Jong et al. 2002. PubMed ID: 12039972). This variant is reported in 0.068% of alleles in individuals of European (non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. -

Hypokalemia;C0151786:Muscle weakness;C0231528:Myalgia;C1522135:Hypermagnesemia Pathogenic:1
Jan 01, 2017
Centre for Mendelian Genomics, University Medical Centre Ljubljana
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.97
BayesDel_addAF
Pathogenic
0.29
D
BayesDel_noAF
Pathogenic
0.55
CADD
Pathogenic
30
DANN
Pathogenic
1.0
DEOGEN2
Pathogenic
0.89
.;.;D;D
Eigen
Pathogenic
0.71
Eigen_PC
Uncertain
0.55
FATHMM_MKL
Pathogenic
1.0
D
LIST_S2
Pathogenic
1.0
D;D;D;D
M_CAP
Pathogenic
0.31
D
MetaRNN
Uncertain
0.70
D;D;D;D
MetaSVM
Uncertain
0.33
D
MutationAssessor
Pathogenic
3.5
.;H;H;.
PhyloP100
9.8
PrimateAI
Pathogenic
0.80
T
PROVEAN
Pathogenic
-7.4
D;D;D;D
REVEL
Pathogenic
0.85
Sift
Pathogenic
0.0
D;D;D;D
Sift4G
Pathogenic
0.0
D;D;D;D
Polyphen
1.0
D;D;D;.
Vest4
0.99
MutPred
0.89
.;Gain of MoRF binding (P = 0.0166);Gain of MoRF binding (P = 0.0166);.;
MVP
0.96
MPC
0.52
ClinPred
0.37
T
GERP RS
3.7
Varity_R
0.94
gMVP
0.94
Mutation Taster
=1/99
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.10
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs138977195; hg19: chr16-56921879; API